Business Wire

CA-TESSERA/FRAUNHOFER

15.9.2016 14:04:35 CEST | Business Wire | Press release

Share
Fraunhofer EMFT Signs Agreement to Implement ZiBond and DBI Technologies in MEMS Applications

Invensas Corporation, a wholly owned subsidiary of Tessera Technologies, Inc., (Nasdaq:TSRA) announced today that Fraunhofer EMFT has signed a new license agreement to incorporate ZiBond® and Direct Bond Interconnect (DBI®) technologies into their portfolio of foundry services. This agreement expands Fraunhofer EMFT’s world-class MEMS manufacturing capabilities with the most advanced 3D integration technologies available.

“ZiBond and DBI technologies are truly enabling bonding and 3D integration technologies for next generation electronic products,” said Dr. Peter Ramm, department head, Heterogeneous System Integration at Fraunhofer EMFT. “We look forward to working with Invensas and our global customer base to demonstrate and further optimize these technologies for MEMS applications on our production equipment,” added Prof. Dr. Christoph Kutter, director of Fraunhofer EMFT.

ZiBond and DBI technologies are cost-effective, versatile 2.5D and 3D semiconductor integration solutions that enable leading edge functionality and accelerate time to market for MEMS and multiple other semiconductor products. ZiBond and DBI bonding can be performed at room temperature without requiring bond pressure. Bonding is typically completed in less than a minute for an entire wafer, substantially reducing manufacturing cost.

“Scaling based on Moore’s Law is becoming increasingly challenging and this is driving demand for our ZiBond and DBI bonding and 3D interconnect technologies, which have been proven in high volume production environments,” said Craig Mitchell, president of Invensas Corporation. “We are pleased that Fraunhofer EMFT, a highly respected MEMS research and 3D heterogeneous integration, development and pilot manufacturing center of excellence, has chosen our ZiBond and DBI technologies to help their customers accelerate the development and commercialization of their next generation MEMS products.”

For more information on ZiBond, DBI and other Invensas solutions, please visit www.invensas.com or www.tessera.com .

About Tessera Technologies, Inc.

Tessera Technologies, Inc., including its Invensas and FotoNation subsidiaries, licenses technologies and intellectual property to customers for use in areas such as mobile computing and communications, memory and data storage, and 3D-IC technologies, among others. Our technologies include semiconductor packaging and interconnect solutions, and computational imaging and computer vision products and solutions for mobile and other vision systems. For more information call +1.408.321.6000 or visit www.tessera.com  or www.invensas.com .

Tessera, the Tessera logo, Invensas, the Invensas logo, are trademarks or registered trademarks of affiliated companies of Tessera Technologies, Inc. in the United States and other countries. All other company, brand and product names may be trademarks or registered trademarks of their respective companies.

About Fraunhofer EMFT

Fraunhofer EMFT conducts cutting-edge applied research into sensors and actuators for people and the environment. The core competences of the research departments in Munich with hundred employees include the fields of silicon technologies, devices and 3D integration, as well as foil technologies, micropumps, sensor materials and the capability of system integration. The real strength of Fraunhofer EMFT lies in the interaction between these areas: after all, innovations often emerge where technologies reach their limits and begin to cross-fertilize.

Safe Harbor Statement

This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected, particularly with respect to the agreement with Fraunhofer and the features, benefits and characteristics of ZiBond and DBI. Material factors that may cause results to differ from the statements made include the plans or operations relating to the businesses of Tessera Technologies, Inc. (the "Company"); market or industry conditions; changes in patent laws, regulation or enforcement, or other factors that might affect the Company's ability to protect or realize the value of its intellectual property; the expiration of license agreements and the cessation of related royalty income; the failure, inability or refusal of licensees to pay royalties; initiation, delays, setbacks or losses relating to the Company's intellectual property or intellectual property litigations, or invalidation or limitation of key patents; fluctuations in operating results due to the timing of new license agreements and royalties, or due to legal costs; the risk of a decline in demand for semiconductors and products utilizing FotoNation technologies; failure by the industry to use technologies covered by the Company's patents; the expiration of the Company's patents; the Company's ability to successfully complete and integrate acquisitions of businesses; the risk of loss of, or decreases in production orders from, customers of acquired businesses; financial and regulatory risks associated with the international nature of the Company's businesses; failure of the Company's products to achieve technological feasibility or profitability; failure to successfully commercialize the Company's products; changes in demand for the products of the Company's customers; limited opportunities to license technologies due to high concentration in the markets for semiconductors and related products and smartphone imaging; and the impact of competing technologies on the demand for the Company's technologies. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. The Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended Dec. 31, 2015 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, include more information about factors that could affect the Company's financial results. The Company assumes no obligation to update information contained in this press release. Although this release may remain available on the Company's website or elsewhere, its continued availability does not indicate that the Company is reaffirming or confirming any of the information contained herein.

TSRA-I

Contact:

PR Agency Contact
Zeno Group
Dan Sorensen, +1 650-801-0944
Dan.sorensen@zenogroup.com
or
Company Contact
Tessera Technologies
Adolph Hunter, +1 408-321-6710
ahunter@tessera.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 12:17:00 CEST | Press release

Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm

Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 11:11:00 CEST | Press release

- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team - Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechno

The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 09:00:00 CEST | Press release

New One-Day Intensive Experience Offered 9 June Ahead of Conference 10-11 June at Tobacco Dock Featuring 10 Stages and 14 Tracks The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights

Samsung Research Reveals Over Half of Europeans Admit to Looking at a Stranger's Phone Screen in Public – With Nearly a Quarter Doing so out of Sheer Curiosity1.4.2026 08:00:00 CEST | Press release

From dating apps to financial details, respondents report seeing a wide range of highly personal information on others' screens 56% of people admit to having looked at strangers’ phone screens accidentally, whereas 24% have done so out of curiosity. 57% identify public transport as the most likely place to notice someone else's screen. While 48%* feel confident they can keep their phone activity private when using it in crowded places, another 52%** acknowledge it is easy to see someone’s screen who is next to you in a public place without trying to look. 33% say they have seen personal content on a stranger’s phone in public. Some smartphone users who have looked at a stranger’s phone screen in public ignore and continue what they were doing (28%) or look away immediately (27%), but others (7%) admit to continuing to look discreetly. The new Samsung Galaxy S26 Privacy Display1 limits side-angle viewing of your screen to protect your privacy in any setting. As millions of Europeans2 ge

RevolKa Reimagines Antibody Engineering with "RevoAb®"1.4.2026 06:30:00 CEST | Press release

A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa’s advanced AI Protein Engineering Engine RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye